QRxPharma Limited, with a United State’s headquarters in Bedminster, announced Thursday that the company’s board of directors has appointed Dr. Edward Rudnic to chief executive officer.
According to the announcement, the appointment comes after Dr. John Holaday stepped down as managing director and CEO.
Rudnic, who has more than 30 years of experience in the life sciences industry, has been the company’s chief operating officer since 2012.
“This change in leadership was set by mutual agreement to address the challenges facing the company,” Peter Farrell, chairman of the board, said in a prepared statement. “We thank John for his seven years of service, dedication and pursuit of bringing to market safer therapies, like Moxduo, for the management of pain.”
Prior to Rudnic being at QRxPharma, he founded Advancis Pharmaceuticals and has previously held senior management positions with Shire Pharmaceuticals, Pharmavene, Schering Ploug and E.R. Squibb, according to the announcement.
ALSO ON NJBIZ: